JW Pharmaceutical Corp (001065) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.132x

Based on the latest financial reports, JW Pharmaceutical Corp (001065) has a cash flow conversion efficiency ratio of 0.132x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩46.92 Billion ≈ $31.79 Million USD) by net assets (₩354.10 Billion ≈ $239.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of JW Pharmaceutical Corp to measure how much of total assets are equity-financed.

JW Pharmaceutical Corp - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how JW Pharmaceutical Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of JW Pharmaceutical Corp to evaluate the quality of earnings relative to operating cash generation.

JW Pharmaceutical Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of JW Pharmaceutical Corp ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Better Home & Finance Holding Company NASDAQ:BETR	-8.972x
Beijing Sanfo Outdoor Products Co Ltd SHE:002780	-0.027x
Imagicaaworld Entertainment Limited NSE:IMAGICAA	0.045x
Prenetics Global Ltd NASDAQ:PRE	0.023x
Unggul Indah Cahaya Tbk JK:UNIC	0.088x
Nongshim Holdi KO:072710	0.015x
First Western Financial Inc NASDAQ:MYFW	0.056x
Qingdao Daneng Environmental Protection Equipment Co Ltd SHG:688501	-0.016x

Annual Cash Flow Conversion Efficiency for JW Pharmaceutical Corp (2014–2024)

The table below shows the annual cash flow conversion efficiency of JW Pharmaceutical Corp from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see JW Pharmaceutical Corp (001065) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩329.49 Billion ≈ $223.29 Million	₩79.39 Billion ≈ $53.80 Million	0.241x	-26.62%
2023-12-31	₩265.44 Billion ≈ $179.89 Million	₩87.16 Billion ≈ $59.07 Million	0.328x	+30.59%
2022-12-31	₩225.76 Billion ≈ $152.99 Million	₩56.76 Billion ≈ $38.47 Million	0.251x	+161.57%
2021-12-31	₩188.54 Billion ≈ $127.77 Million	₩18.12 Billion ≈ $12.28 Million	0.096x	-68.37%
2020-12-31	₩207.47 Billion ≈ $140.60 Million	₩63.05 Billion ≈ $42.73 Million	0.304x	+25.93%
2019-12-31	₩230.09 Billion ≈ $155.93 Million	₩55.53 Billion ≈ $37.63 Million	0.241x	+20.47%
2018-12-31	₩260.11 Billion ≈ $176.27 Million	₩52.11 Billion ≈ $35.31 Million	0.200x	+62.17%
2017-12-31	₩270.78 Billion ≈ $183.50 Million	₩33.45 Billion ≈ $22.67 Million	0.124x	+406.54%
2016-12-31	₩276.31 Billion ≈ $187.25 Million	₩6.74 Billion ≈ $4.57 Million	0.024x	+231.67%
2015-12-31	₩225.41 Billion ≈ $152.75 Million	₩-4.17 Billion ≈ $-2.83 Million	-0.019x	-155.99%
2014-12-31	₩220.02 Billion ≈ $149.11 Million	₩7.28 Billion ≈ $4.93 Million	0.033x	--

About JW Pharmaceutical Corp

KO:001065 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$285.31 Million

₩421.01 Billion KRW

Market Cap Rank

#14890 Global

#472 in Korea

Share Price

₩20950.00

Change (1 day)

+0.72%

52-Week Range

₩19800.00 - ₩29850.00

All Time High

₩88605.96